Hand Transplantation — CPB 0816 | AETNA Coverage Update

Aetna, a CVS Health company, updated CPB 0816 — its hand transplantation coverage policy — effective December 4, 2025. Here's what billing teams need to know.

Aetna classifies both hand transplantation and multi-digit allotransplantation for metacarpal hand reconstruction as experimental, investigational, or unproven. This modified policy under CPB 0816 Aetna system affects claims tied to traumatic amputation codes across the S48, S58, and S68 ICD-10-CM ranges. If your practice handles upper extremity reconstruction or works with hand surgery programs that have explored transplantation, this coverage policy belongs on your radar now — not after the first denial lands.

Quick-Reference Table

Aetna Hand Transplantation Coverage Policy and Medical Necessity Requirements 2025

The short answer on medical necessity here: Aetna won't find it. Under CPB 0816, Aetna does not recognize hand transplantation or multi-digit allotransplantation as medically necessary procedures. Both are classified as experimental, investigational, or unproven.

That classification has a specific meaning in the billing world. It means Aetna has determined there is insufficient evidence of clinical effectiveness to support coverage. No amount of documentation, no letter of medical necessity, and no peer-to-peer review will change that outcome under this coverage policy. The denial is policy-level, not documentation-level.

This matters for your prior authorization workflow. Don't submit prior authorization requests for hand transplantation or multi-digit allotransplantation expecting approval. If your team is pursuing a transplant program and Aetna is one of your payer contracts, that prior auth will come back denied. The better use of your time is identifying those patients before surgery and addressing the financial pathway — self-pay agreements, transplant program grants, or out-of-network case rates — not chasing a reimbursement that won't come.

The related policy to know here is CPB 0399, which governs upper limb prostheses. If your team is pivoting from transplantation to prosthetic reconstruction for Aetna members, that's the policy that controls what Aetna will actually pay for. Billing guidelines for prosthetic coverage differ significantly from transplant billing, and conflating the two will generate denials in both directions.

Aetna Hand Transplantation Exclusions and Non-Covered Indications

Aetna's position under CPB 0816 covers two specific procedures. Both are fully excluded from coverage.

Hand transplantation — This is composite tissue allotransplantation involving the hand and wrist. Aetna considers this experimental across all indications. There is no covered subgroup, no diagnosis-specific exception, and no plan-level carve-in for this procedure.

Multi-digit allotransplantation for reconstruction of the metacarpal hand — This is the surgical reconstruction of a hand that has lost multiple digits at or near the metacarpal level, using donor tissue allografts. Aetna considers this experimental as well. The metacarpal hand is a specific anatomical presentation — a hand where the digits are amputated but the palm and metacarpals remain intact. Even in this reconstructive context, Aetna draws a hard line.

The real issue here is that these exclusions aren't new to 2025. Aetna has held this position on hand transplantation for years. What the December 4, 2025 modification signals is a policy review and reaffirmation. That reaffirmation matters because it tells you Aetna is not moving toward coverage. Some experimental designations soften over time as evidence accumulates. This one is holding.

For billing teams working with hand surgery programs that participate in research protocols or reconstructive transplant centers, this policy creates a documentation and communication challenge. Your clinical team may believe — correctly — that a patient is a strong transplant candidate. Aetna's coverage policy position makes the payer's answer irrelevant to that clinical judgment. The financial exposure falls on the patient or the program.

If your program is doing any of this work and billing Aetna, loop in your compliance officer before the effective date has passed without a clear protocol in place.

Coverage Indications at a Glance

Aetna Hand Transplantation Billing Guidelines and Action Items 2025

CPT, HCPCS, and ICD-10 Codes for Hand Transplantation Under CPB 0816

The CPB 0816 policy document does not list specific CPT or HCPCS procedure codes. Aetna's policy is a categorical exclusion — it covers all hand transplantation and multi-digit allotransplantation regardless of the procedure code used to bill it. For procedure-level code mapping, work with your hand surgery team and your coding team to identify the specific CPT codes being used in your program, then confirm Aetna's position on each with your provider relations contact.

Key ICD-10-CM Diagnosis Codes Under CPB 0816

These are the diagnosis code ranges cited in the policy. They cover traumatic amputation across the upper extremity. These codes are relevant both to the transplantation procedures Aetna excludes and to the prosthetic pathway under CPB 0399.

The "+" notation on these codes indicates that a 7th character extension is required for complete ICD-10-CM coding — typically A (initial encounter), D (subsequent encounter), or S (sequela). Make sure your coding team applies the correct encounter-type character. Missing or incorrect 7th characters on these codes generate claim edits before the denial even reaches the medical necessity level.